These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15893893)

  • 1. Topical absorption of piroxicam from organogels--in vitro and in vivo correlations.
    Pénzes T; Blazsó G; Aigner Z; Falkay G; Eros I
    Int J Pharm; 2005 Jul; 298(1):47-54. PubMed ID: 15893893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and characterization of reverse micelle based organogels of piroxicam.
    Agrawal GP; Juneja M; Agrawal S; Jain SK; Pancholi SS
    Pharmazie; 2004 Mar; 59(3):191-3. PubMed ID: 15074590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal lontophoresis and skin retention of piroxicam from gels containing piroxicam: hydroxypropyl-beta-cyclodextrin complexes.
    Doliwa A; Santoyo S; Ygartua P
    Drug Dev Ind Pharm; 2001 Sep; 27(8):751-8. PubMed ID: 11699826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of formulated tenoxicam transdermal delivery systems.
    Kim T; Kang E; Chun I; Gwak H
    J Pharm Pharmacol; 2008 Jan; 60(1):135-8. PubMed ID: 18088513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing effects of fatty acids on piroxicam permeation through rat skins.
    Shin SC; Shin EY; Cho CW
    Drug Dev Ind Pharm; 2000 May; 26(5):563-6. PubMed ID: 10789070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced efficacy by percutaneous absorption of piroxicam from the poloxamer gel in rats.
    Shin S; Cho C; Oh I
    Int J Pharm; 2000 Jan; 193(2):213-8. PubMed ID: 10606784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of skin pretreatment with fatty acids on percutaneous absorption and skin retention of piroxicam after its topical application.
    Santoyo S; Ygartua P
    Eur J Pharm Biopharm; 2000 Sep; 50(2):245-50. PubMed ID: 10962234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin.
    Gwak HS; Chun IK
    Int J Pharm; 2002 Apr; 236(1-2):57-64. PubMed ID: 11891070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of non-ionic surfactants, pH and propylene glycol on percutaneous absorption of piroxicam from cataplasm.
    Okuyama H; Ikeda Y; Kasai S; Imamori K; Takayama K; Nagai T
    Int J Pharm; 1999 Sep; 186(2):141-8. PubMed ID: 10486432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo percutaneous absorption of topical dosage forms: case studies.
    Csóka I; Csányi E; Zapantis G; Nagy E; Fehér-Kiss A; Horváth G; Blazsó G; Eros I
    Int J Pharm; 2005 Mar; 291(1-2):11-9. PubMed ID: 15707727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro percutaneous absorption of piroxicam through synthetic membranes and abdominal rat skin.
    Santoyo S; Arellano A; Ygartua P; Martín C
    Pharm Acta Helv; 1996 Jul; 71(2):141-6. PubMed ID: 8810580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transbuccal permeation, anti-inflammatory activity and clinical efficacy of piroxicam formulated in different gels.
    Attia MA; El-Gibaly I; Shaltout SE; Fetih GN
    Int J Pharm; 2004 May; 276(1-2):11-28. PubMed ID: 15113610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical piroxicam in vitro release and in vivo anti-inflammatory and analgesic effects from palm oil esters-based nanocream.
    Abdulkarim MF; Abdullah GZ; Chitneni M; Salman IM; Ameer OZ; Yam MF; Mahdi ES; Sattar MA; Basri M; Noor AM
    Int J Nanomedicine; 2010 Nov; 5():915-24. PubMed ID: 21116332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
    Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
    J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of piroxicam absorption by oral mucosa.
    Diez-Ortego I; Cruz M; Largo R; Navarro A; Palacios I; Solans A; Sanchez-Pernaute O; Egido J; Herrero-Beaumont G
    Arzneimittelforschung; 2002; 52(5):385-7. PubMed ID: 12087924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New microemulsion vehicle facilitates percutaneous penetration in vitro and cutaneous drug bioavailability in vivo.
    Sintov AC; Shapiro L
    J Control Release; 2004 Mar; 95(2):173-83. PubMed ID: 14980766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pectin microspheres as ophthalmic carriers for piroxicam: evaluation in vitro and in vivo in albino rabbits.
    Giunchedi P; Conte U; Chetoni P; Saettone MF
    Eur J Pharm Sci; 1999 Oct; 9(1):1-7. PubMed ID: 10493990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam.
    Li F; Song S; Guo Y; Zhao Q; Zhang X; Pan W; Yang X
    Drug Deliv; 2015; 22(4):487-98. PubMed ID: 24524289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect.
    Dalmora ME; Dalmora SL; Oliveira AG
    Int J Pharm; 2001 Jul; 222(1):45-55. PubMed ID: 11404031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the surfactant on the availability of piroxicam as a poorly hydrosoluble drug from suppositories.
    Dal Zorro M; Franceschinis E; Punchina A; Realdon N
    Pharmazie; 2012 Jan; 67(1):37-45. PubMed ID: 22393829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.